#None #Wet AMD #REGENXBIO #Adverum Biotechnologies

Wet AMD Market Set for Robust Growth Through 2036

The wet age-related macular degeneration (wet AMD) market is on the brink of substantial growth, driven by a surge in diagnosed cases, advancements in treatment methodologies, and the introduction of innovative therapies. Recent insights reveal a promising landscape for this segment, forecasting notable expansions through 2036.

1. Market Overview

Wet AMD, which represents approximately 10% of all AMD cases, is responsible for nearly 90% of severe central vision loss linked to the disease. The increasing prevalence of the disease correlates directly with the aging global population, as wet AMD predominantly affects individuals aged 60 and above.

The market currently benefits from a diverse range of treatment options, including established anti-VEGF therapies that prevent vision loss. New entries into the therapeutic landscape, such as Ixoberogene soroparvovec (Ixo-vec) from Adverum Biotechnologies and RGX-314 from Regenxbio/AbbVie, are poised to enhance treatment effectiveness significantly.

2. Demand Drivers

2.1 Aging Population

The geriatric demographic, which is increasing in numbers, serves as a primary driver for market growth. Expanding life expectancy is creating a larger patient pool, necessitating advanced treatment solutions.

2.2 Technological Innovations

Recent advancements in diagnostic technologies, such as optical coherence tomography (OCT), have improved early detection and monitoring of wet AMD. Moreover, the development of AI-driven diagnostic tools promises to optimize care pathways and enhance patient outcomes.

2.3 Gene and Stem Cell Therapies

Emerging therapies utilizing gene and stem cell technologies are altering the treatment paradigm for wet AMD. These next-generation therapies, which include promising candidates like RGX-314 and Ixo-vec, provide longer-lasting solutions, potentially reducing the need for frequent injections and enhancing patient adherence.

2.4 Robust Therapeutics Pipeline

The competitive landscape features a robust pipeline of new therapies at various stages of development. Notable candidates include OGX-110 from Ocugenix, AKST4290 from Alkahest, and others, all of which are driving innovation in the sector and attracting significant investment from major players such as AbbVie and Roche.

3. Current Treatments

At present, intravitreal anti-VEGF therapy ranks as the leading treatment modality for wet AMD. Approved agents such as aflibercept (EYLEA) and ranibizumab (LUCENTIS) are widely utilized by retina specialists. Additionally, biosimilars have entered the market, offering more cost-effective options for patients and healthcare providers.

The forecast from the current landscape indicates a continuous evolution of treatment options, with new drugs aiming to enhance the efficacy and safety of existing therapies. For instance, bevacizumab (LYTENAVA), which received its first approval for wet AMD in the EU on May 28, 2024, exemplifies ongoing innovations and regulatory efforts within the section.

4. Competitive Landscape

Industry players are actively pursuing research to establish their products in the wet AMD space. Adverum Biotechnologies, with its gene therapy candidate Ixoberogene soroparvovec (Ixo-vec), aims to provide a one-time treatment alternative to existing therapies, receiving multiple designations from regulatory bodies that expedite its development.

Regenxbio’s RGX-314 is focused on delivering a gene encoding a monoclonal antibody fragment via a subretinal route, offering potential benefits as a one-time therapy instead of repeated injections, which helps simplify treatment regimens for patients.

Moreover, ongoing clinical trials and the anticipated launching of these candidate products underscore the market's momentum, unlocking new standards of care and enhancing opportunities for clinical efficacy and patient satisfaction.

5. Future Outlook

Projected growth in the wet AMD market through 2036 reflects the confluence of factors that include an aging population, technological innovation, and the continual development of new therapies. As these emerging treatments progress through clinical trials and regulatory scrutiny, their integration into the standard care pathway is poised to revolutionize how wet AMD is managed globally.

Ensuring consistent research and innovation, coupled with a willingness to adapt clinical practices, will be crucial in enhancing the quality of life for millions affected by wet AMD. Notably, while challenges persist regarding cost and patient-specific variables, the continual evolution of therapies holds noteworthy promise for the future landscape of wet AMD treatment.